Victoria Marty, MLaw

Switzerland

Victoria Marty, MLaw

Victoria Marty primarily advises companies and investors on private equity, venture capital and M&A transactions. She also supports clients on corporate and regulatory matters, the design of effective corporate governance structures and general contract law. Her approach combines careful legal analysis with a practical understanding of of her clients' commercial and strategic objectives.

Details

  • Zurich Bar Association
  • Attorney at law (Swiss bar admission, 2020)
  • Senior Associate at act legal Switzerland (since 2020, formerly BGPartner Ltd)
  • Cantonal Court of Zug
  • Leading Swiss law firm
  • University of Zurich, MLaw
  • German
  • English

news

track-records

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.

Advising lead investor Novo Holdings and new investor LifeArc Ventures on the oversubscribed USD 130 million Series B financing of GlycoEra Ltd.

Advising lead investor Novo Holdings and new investor LifeArc Ventures on the oversubscribed USD 130 million Series B financing of GlycoEra Ltd.

Advising OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on all Swiss law aspects of the USD 165 million Series B financing of Windward Bio Group AG, including the related negotiations.

Advising OrbiMed, Novo Holdings, Blue Owl Capital and Omega Funds on all Swiss law aspects of the USD 165 million Series B financing of Windward Bio Group AG, including the related negotiations.

Advising co-lead investors Forbion and Jeito Capital on the oversubscribed Series B financing of Noema Pharma Ltd of approximately USD 112 million.

Advising co-lead investors Forbion and Jeito Capital on the oversubscribed Series B financing of Noema Pharma Ltd of approximately USD 112 million.

Advising Memo Therapeutics Ltd on its CHF 25 million Series C financing round led by Pureos Bioventures.

Advising Memo Therapeutics Ltd on its CHF 25 million Series C financing round led by Pureos Bioventures.

Advising Memo Therapeutics Ltd on the CHF 20 million extension of its Series C financing, bringing the round to CHF 45 million.

Advising Memo Therapeutics Ltd on the CHF 20 million extension of its Series C financing, bringing the round to CHF 45 million.

Advising lead investor Novo Holdings together with EQT Life Sciences, OrbiMed and SR One on the oversubscribed USD 100 million Series C financing of Asceneuron SA.

Advising lead investor Novo Holdings together with EQT Life Sciences, OrbiMed and SR One on the oversubscribed USD 100 million Series C financing of Asceneuron SA.

Advising OrbiMed, Novo Holdings and Catalio Capital on the oversubscribed USD 181.4 million Series D financing of Alentis Therapeutics AG.

Advising OrbiMed, Novo Holdings and Catalio Capital on the oversubscribed USD 181.4 million Series D financing of Alentis Therapeutics AG.

Advising EQT, Forbion and Jeito on the extension of the Series B financing of Noema Pharma Ltd to USD 147 million.

Advising EQT, Forbion and Jeito on the extension of the Series B financing of Noema Pharma Ltd to USD 147 million.

Advising OrbiMed and Novo Holdings on the USD 200 million Series A financing of Windward Bio Group AG.

Advising OrbiMed and Novo Holdings on the USD 200 million Series A financing of Windward Bio Group AG.

Advising Forbion, Novo Holdings and HBM Healthcare Investments on the Series C top-up financing of Numab Therapeutics Ltd, raising the round to CHF 180 million.

Advising Forbion, Novo Holdings and HBM Healthcare Investments on the Series C top-up financing of Numab Therapeutics Ltd, raising the round to CHF 180 million.

Advising the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund (EQT) and SR One on the two largest Swiss financing rounds of 2024, as recorded in the Swiss Venture Capital Report 2025.

Advising the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund (EQT) and SR One on the two largest Swiss financing rounds of 2024, as recorded in the Swiss Venture Capital Report 2025.

Victoria Marty, MLaw

Share via email

act legal BGPartner Ltd
General-Guisan-Quai 38
CH-8027 Zurich
Switzerland

Go to
Offices

Go to Offices